IMP dehydrogenase: structural schizophrenia and an unusual base

Current Opinion in Chemical Biology

Volumn 10, Issue 5, 2006, Pages 520-525

  Hedstrom, Lizbeth ^a   Gan, Lu ^b  

^a BRANDEIS UNIVERSITY   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTIVIRUS AGENT; BACTERIAL ENZYME; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MIZORIBINE; MIZORIBINE MONOPHOSPHATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RIBAVIRIN; TIAZOFURIN; UNCLASSIFIED DRUG;

CATALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; MAMMAL; REVIEW;

ANIMALS; BINDING SITES; CATALYSIS; ENZYME ACTIVATION; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; IMP DEHYDROGENASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEIC ACIDS; PROTEIN CONFORMATION;

EID: 33748519900     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2006.08.005     Document Type: Review

References (39)

1. Pankiewicz K.W., Lesiak-Watanabe K.B., Watanabe K.A., Patterson S.E., Jayaram H.N., Yalowitz J.A.M.M., Seidman M., Majumdar A., Prehna G., and Goldstein B.M. Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem 45 (2002) 703-712
2. Dhar T.G., Shen Z., Guo J., Liu C., Watterson S.H., Gu H.H., Pitts W.J., Fleener C.A., Rouleau K.A., Sherbina N.Z., et al. Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methy l-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem 45 (2002) 2127-2130
3. Pankiewicz K.W., Patterson S.E., Black P.L., Jayaram H.N., Risal D., Goldstein B.M., Stuyver L.J., and Schinazi R.F. Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target. Curr Med Chem 11 (2004) 887-900
4. Jager W., Salamon A., and Szekeres T. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr Med Chem 9 (2002) 781-786
5. Yalowitz J.A., and Jayaram H.N. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res 20 (2000) 2329-2338
6. Sintchak M.D., and Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47 (2000) 163-184
7. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
8. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 6 (1999) 575-597
9. Franchetti P., and Grifantini M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem 6 (1999) 599-614
10. Jayaram H.N., Cooney D.A., and Grusch M. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem 6 (1999) 561-574
11. Goldstein B.M., and Colby T.D. IMP dehydrogenase: structural aspects of inhibitor binding. Curr Med Chem 6 (1999) 519-536
12. Hedstrom L. IMP dehydrogenase: mechanism of action and inhibition. Curr Med Chem 6 (1999) 545-560
13. Cornuel J.F., Moraillon A., and Gueron M. Participation of yeast inosine 5′-monophosphate dehydrogenase in an in vitro complex with a fragment of the C-rich telomeric strand. Biochimie 84 (2002) 279-289
14. McLean J.E., Hamaguchi N., Belenky P., Mortimer S.E., Stanton M., and Hedstrom L. Inosine 5′-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo. Biochem J 379 (2004) 243-251
15. Bowne S.J., Sullivan L.S., Blanton S.H., Cepko C.L., Blackshaw S., Birch D.G., Hughbanks-Wheaton D., Heckenlively J.R., and Daiger S.P. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet 11 (2002) 559-568
16. Kennan A., Aherne A., Palfi A., Humphries M., McKee A., Stitt A., Simpson D.A., Demtroder K., Orntoft T., Ayuso C., et al. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet 11 (2002) 547-557
17. Aherne A., Kennan A., Kenna P.F., McNally N., Lloyd D.G., Alberts I.L., Kiang A.S., Humphries M.M., Ayuso C., Engel P.C., et al. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Hum Mol Genet 13 (2004) 641-650
18. Mortimer S.E., and Hedstrom L. Autosomal dominant retinitis pigmentosa mutations in inosine 5′-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem J 390 (2005) 41-47
19. Bowne S.J., Sullivan L.S., Mortimer S.E., Hedstrom L., Zhu J., Spellicy C.J., Gire A.I., Hughbanks-Wheaton D., Birch D.G., Lewis R.A., et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci 47 (2006) 34-42
20. Whitehead J.P., Simpson F., Hill M.M., Thomas E.C., Connolly L.M., Collart F., Simpson R.J., and James D.E. Insulin and oleate promote translocation of inosine-5' monophosphate dehydrogenase to lipid bodies. Traffic 5 (2004) 739-749
21. Digits J.A., and Hedstrom L. Kinetic mechanism of tritrichomonas foetus inosine-5′-monophosphate dehydrogenase. Biochemistry 38 (1999) 2295-2306
22. Link J.O., and Straub K. Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid. J Am Chem Soc 118 (1996) 2091-2092
23. Sintchak M.D., Fleming M.A., Futer O., Raybuck S.A., Chambers S.P., Caron P.R., Murcko M., and Wilson K.P. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85 (1996) 921-930
24. Umejiego N.N., Li C., Riera T., Hedstrom L., and Striepen B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural and dynamic properties that can be exploited for drug design. J Biol Chem 279 (2004) 40320-40327
25. Kerr K. The role of carboxylate residues in the mechanism of E. coli IMP dehydrogenase (1998), Brandeis University, Waltham, MA
26. Gan L., Seyedsayamdost M.R., Shuto S., Matsuda A., Petsko G.A., and Hedstrom L. The immunosuppressive agent mizoribine monophosphate forms a transition state analog complex with IMP dehydrogenase. Biochemistry 42 (2003) 857-863. Reveals the closed conformation of the flap and explains the surprising transition state analogy of MZP.
27. Guillén Schlippe Y.V., Riera T.V., Seyedsayamdost M.R., and Hedstrom L. Substitution of the conserved Arg-Tyr dyad selectively disrupts the hydrolysis phase of the IMP dehydrogenase reaction. Biochemistry 43 (2004) 4511-4521. Dissection of the effects of mutations of Arg418-Try419 on individual steps in the IMPDH reaction, showing that these mutations specifically perturb the hydrolysis of E-XMP*.
28. McPhillips C.C., Hyle J.W., and Reines D. Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo. Proc Natl Acad Sci USA 101 (2004) 12171-12176
29. Kohler G.A., Gong X., Bentink S., Theiss S., Pagani G.M., Agabian N., and Hedstrom L. The functional basis of mycophenolic acid resistance in Candida albicans IMP dehydrogenase. J Biol Chem 280 (2005) 11295-11302. This paper describes a mutation that stabilizes the closed conformation, installing MPA resistance but increasing sensitivity to MZP.
30. Jenks M.H., and Reines D. Dissection of the molecular basis of mycophenolate resistance in Saccharomyces cerevisiae. Yeast 22 (2005) 1181-1190
31. Whitby F.G., Luecke H., Kuhn P., Somoza J.R., Huete-Perez J.A., Philips J.D., Hill C.P., Fletterick R.J., and Wang C.C. Crystal structure of Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase and the enzyme-product complex. Biochemistry 36 (1997) 10666-10674
32. Gan L., Petsko G.A., and Hedstrom L. Crystal structure of a ternary complex of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase: NAD orients the active site loop for catalysis. Biochemistry 41 (2002) 13309-13317
33. Prosise G.L., Wu J.Z., and Luecke H. Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site. J Biol Chem 277 (2002) 50654-50659. Traps a putative sodium ion interacting with the loop that contains the catalytic Cys and proposes a dynamic role for monovalent cation activation.
34. Prosise G.L., and Luecke H. Crystal structures of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism. J Mol Biol 326 (2003) 517-527
35. Guillén Schlippe Y.V., and Hedstrom L. Is Arg418 the catalytic base required for the hydrolysis step of the IMP dehydrogenase reaction?. Biochemistry 44 (2005) 11700-11707. The Gln and Lys mutations of Arg418 uncouple the conformational change from hydrolysis.
36. Guillén Schlippe Y.V., and Hedstrom L. Guanidine derivatives rescue the Arg418Ala mutation of Tritrichomonas foetus IMP dehydrogenase. Biochemistry 44 (2005) 16695-16700
37. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF chimera- a visualization system for exploratory research and analysis. J Comput Chem 25 (2004) 1605-1612
38. Ji Y., Gu J., Makhov A.M., Griffith J.D., Mitchell B.S., Ji Y., Gu J., Makhov A.M., Griffith J.D., and Mitchell B.S. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP. J Biol Chem 281 (2006) 206-212. IMPDH aggregates in response to drug treatment in vivo and in vitro.
39. Chong C.R., Qian D.Z., Pan F., Wei Y., Pili R., Sullivan Jr. D.J., and Liu J.O. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 49 (2006) 2677-2680. Challenges the prevailing view that specific inhibitors of the type II isozyme would improve cancer chemotherapy.